Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Yartemlia's first full quarter performance was driven by a significant shift toward adult transplant centers, which now represent approximately 75% of sales compared to initial pediatric-heavy utilization.
Management is actively working to transition the clinical paradigm from treating TA-TMA as a 'diagnosis of exclusion' to proactive screening, which is expected to increase the identified patient population. The company achieved positive operational cash flow of $4.1 million, supported by strong net sales growth of 188% quarter-over-quarter and disciplined commercial execution. Strategic capital restructuring through share and note repurchases reduced the potential fully diluted share count by 5.8 million shares and eliminated $8.6 million in future interest payments.
Market penetration is accelerating with 73 unique accounts ordering as of June 30, representing a 143% increase since the end of the first quarter. The launch strategy focuses on securing institutional access, with formulary approval already reached at approximately 55% to 60% of tracked top-tier U.S. transplant centers. Management reaffirmed expectations to be company-wide cash flow positive by mid-2027, supported by current commercial momentum and the Novo Nordisk milestone structure.
The company is pursuing a re-examination of the European marketing authorization for Yartemlia following a negative CHMP opinion, utilizing an independent expert group to review pivotal data. Pipeline expansion plans include initiating two investigator-sponsored studies by year-end for hyperinflammatory ARDS and prophylactic use in pediatric TA-TMA. Development of the MASP-2 platform continues with the finalization of Phase 2 indications for the long-acting antibody OMS1030 and candidate selection for the oral small molecule program.
Revenue guidance remains withheld as management seeks more experience with prescribing trends, patient demand, and the impact of upcoming reimbursement milestones. A permanent J-code became effective July 1, and a New Technology Add-on Payment (NTAP) providing up to $287,000 in additional reimbursement is scheduled for October 1. The company recorded a $12.1 million non-cash mark-to-market gain on embedded derivatives, a volatile figure tied directly to fluctuations in the common stock price.
A $1.9 million loss was recognized in connection with the June agreement to repurchase convertible notes, reflecting the difference between fair value and carrying amount. Management noted that while pediatric adoption was rapid, institutional inertia at large academic centers remains a challenge for shifting diagnostic standards. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
